BrightSpring (BTSG) Reports Strong Q3 2026 Growth Driven by Specialty Pharmacy and Acquisitions
BrightSpring Health Services, Inc. (BTSG) delivered robust third-quarter 2026 results, headlined by a 26.4% year-over-year increase in net revenue to $4.213 billion. The company's growth was primarily fueled by significant volume increases in specialty and infusion services, alongside the successful integration of home health acquisitions from Amedisys and LHC branches. Despite strong top-line performance, management highlighted headwinds from the Inflation Reduction Act (IRA), which impacted Home and Community Pharmacy revenue. The company expects a total annual IRA impact of approximately $200 million for 2026. However, overall profitability remains high, with Adjusted EBITDA rising 42% year-over-year to $228 million and Adjusted EPS increasing 80% to $0.54.
Topics: Acquisitions Adjusted EBITDA Inflation Reduction Act Impact Net Revenue Growth Specialty Pharmacy